首页 > 市场调查报告书 > 製药

非专利药糖尿病生物製剂生技仿製药

市场调查报告书

商品编码

1673957

Insulin Glargine市场按类型、糖尿病类型、分销管道和地区划分

Insulin Glargine Market, By Type, By Diabetes Type, By Distribution Channel, By Geography

出版日期: 2025年02月20日 | 出版商:

Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球Insulin Glargine市场规模估计为 58.1 亿美元，预计到 2032 年将达到 90.9 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 6.6%。

报告范围		报告详细信息
基准年	2024	2025 年市场规模	58.1亿美元
效能资料	2020-2024	预测期	2025-2032
预测期：2025 年至 2032 年复合年增长率	6.60%	2032 年金额预测	90.9 亿美元

数字。 2025 年Insulin Glargine市场占有率（按地区分列）

Insulin Glargine，也称为 Lantus，是一种用于治疗糖尿病的长效基础胰岛素。它是透过重组 DNA 技术製成的合成人类胰岛素，可溶解于酸性环境中。注射后，它会在皮下组织中沉淀形成结晶，然后形成储存库，胰岛素会从储存库逐渐被吸收到血液中。这种缓释性和作用持续时间的特性可以为 1 型和 2 型糖尿病患者提供 24 小时的血糖值控制，每日一次即可。与其他基础胰岛素製剂Insulin Detemir和中性胰岛素相比，Insulin Glargine的吸收速度较慢，有助于维持血液中更平稳、更一致的胰岛素水平。

市场动态

全球Insulin Glargine市场的成长受到全球糖尿病盛行率上升的推动。国际糖尿病联盟 (2021) 估计，2021 年将有超过 5.37 亿成年人患有糖尿病，预计到 2030 年这一数字将增至 6.43 亿，到 2045 年将增至 7.83 亿。老年人口的增加也促进了市场的成长，因为糖尿病在老年人口中更为普遍。然而，成本限制是一个限制因素，尤其是在发展中国家。从积极的一面来看，更有效、更便捷的药物传输技术的开发正在创造新的机会。

研究的主要特点

本报告对全球Insulin Glargine市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球Insulin Glargine市场的主要企业概况。
本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球Insulin Glargine市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过全球Insulin Glargine市场分析中使用的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 5.81 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.60%	2032 Value Projection:	USD 9.09 Bn

Insulin glargine, also known as Lantus, is a long-acting basal insulin that is used for the treatment of diabetes mellitus. It is a synthetic form of human insulin created through recombinant DNA technology, engineered to be soluble in acidic environments. Upon injection, it precipitates and forms microcrystals in the subcutaneous tissue, creating a depot from which insulin is gradually absorbed into the bloodstream. This extended release and duration of action profile allows once-daily dosing to help control blood glucose levels in patients with type 1 and type 2 diabetes over 24 hours. Insulin glargine has a slower absorption profile as compared to other basal insulins such as insulin detemir and insulin NPH, and thus, provides a smooth and consistent level of insulin in the blood.

Market Dynamics:

Global insulin glargine market growth is driven by growing prevalence of diabetes worldwide. According to estimates by the International Diabetes Federation 2021, over 537 million adults lived with diabetes in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Increasing geriatric population also contributes to market growth since diabetes is more common in older age groups. However, cost constraints, especially in developing countries, acts as a restrain. On the positive side, ongoing development of more effective and convenient drug delivery technologies is expected to present new opportunities.

Key Features of the Study:

This report provides in-depth analysis of the global insulin glargine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global insulin glargine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, and Viatris Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation

Type:
- Lantus
- Basaglar
- Toujeo
- Soliqua/Suliqua
- Others
Diabetes Type:
- Type 2 Diabetes
- Type 1 Diabetes
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles:
- Sanofi
- Biocon
- Eli Lilly and Company
- Boehringer Ingelheim
- Gan & Lee
- Kalbe Pharma
- Polus Biopharm
- Samsung Bioepis
- Wockhardt
- Novo Nordisk AS
- Julphar
- Viatris Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Diabetes Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of diabetes worldwide
- High cost of insulin glargine
- Increase in awareness about diabetes management
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Insulin Glargine Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Insulin Glargine Market, By Type, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Basaglar
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Toujeo
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Soliqua/Suliqua
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

6. Global Insulin Glargine Market, By Diabetes Type, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

7. Global Insulin Glargine Market, By Distribution Channel, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

8. Global Insulin Glargine Market, By Region, 2020-2032, (USD BN)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD BN)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gan & Lee
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kalbe Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Polus Biopharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wockhardt
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

10. Analyst View

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

Insulin Glargine市场按类型、糖尿病类型、分销管道和地区划分